Stay updated on High Dose Cytarabine + Pembrolizumab in AML Clinical Trial
Sign up to get notified when there's something new on the High Dose Cytarabine + Pembrolizumab in AML Clinical Trial page.

Latest updates to the High Dose Cytarabine + Pembrolizumab in AML Clinical Trial page
- ChecktodayChange DetectedThe page now displays revision v3.7.0, replacing the previous v3.6.6. This indicates the study page has been updated to a newer version.SummaryDifference0.1%

- Check8 days agoNo Change Detected
- Check15 days agoChange DetectedRevision updated from v3.6.5 to v3.6.6, indicating a small backend/template update for the study page. This update does not alter the study details, eligibility criteria, or locations; it seems to be a platform version bump.SummaryDifference0.1%

- Check22 days agoNo Change Detected
- Check36 days agoChange DetectedThis change updates the page's underlying version from v3.6.4 to v3.6.5, indicating a small maintenance update to the template or platform without modifying the study details.SummaryDifference0.1%

- Check50 days agoChange DetectedThe page shows a revision tag updated from v3.6.3 to v3.6.4, indicating a minor software update to the underlying system. This is a technical version bump and does not change the clinical trial details or visible content.SummaryDifference0.1%

- Check78 days agoChange DetectedThe revision label was updated from v3.6.0 to v3.6.3, indicating a minor update to the document history. The change reflects a version bump rather than a substantive modification to the study details.SummaryDifference0.1%

- Check93 days agoChange DetectedThe page now shows a recruitment status, and adds guidance sections for reading the study record and joining the study. The Interventions/Treatment label is reformatted and the revision tag updated from v3.5.5 to v3.6.0.SummaryDifference0.5%

Stay in the know with updates to High Dose Cytarabine + Pembrolizumab in AML Clinical Trial
Enter your email address, and we'll notify you when there's something new on the High Dose Cytarabine + Pembrolizumab in AML Clinical Trial page.